01-Apr-2025
M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment
|
M1 Kliniken AG / Key word(s): Investment/Miscellaneous M1 Kliniken AG: HAEMATO AG is reviewing an offer for the sale of its trading segment HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer. A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business. The company will provide further information in due course. Contact: Attila Strauss, Management Board Corporate Communications E-Mail: ir@m1-kliniken.de End of Inside Information
01-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2110090 |
| End of Announcement | EQS News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website:
Last Updated: 01-Apr-2025
